CN112851683A - 游离碱晶体 - Google Patents

游离碱晶体 Download PDF

Info

Publication number
CN112851683A
CN112851683A CN202110144523.3A CN202110144523A CN112851683A CN 112851683 A CN112851683 A CN 112851683A CN 202110144523 A CN202110144523 A CN 202110144523A CN 112851683 A CN112851683 A CN 112851683A
Authority
CN
China
Prior art keywords
methyl
crystals
solvate
free base
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110144523.3A
Other languages
English (en)
Chinese (zh)
Inventor
安倍隆
G·巴克顿
R·戴维斯
M·霍珀
P·李
丸山秀明
高须正浩
L·P·文诺格勒
山本裕平
山下弘典
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CN112851683A publication Critical patent/CN112851683A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202110144523.3A 2013-06-21 2014-06-20 游离碱晶体 Pending CN112851683A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838105P 2013-06-21 2013-06-21
US61/838,105 2013-06-21
US201361919424P 2013-12-20 2013-12-20
US61/919,424 2013-12-20
CN201480046150.4A CN105658222A (zh) 2013-06-21 2014-06-20 游离碱晶体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480046150.4A Division CN105658222A (zh) 2013-06-21 2014-06-20 游离碱晶体

Publications (1)

Publication Number Publication Date
CN112851683A true CN112851683A (zh) 2021-05-28

Family

ID=52105535

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110144523.3A Pending CN112851683A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN201480046150.4A Pending CN105658222A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN201910526464.9A Pending CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201480046150.4A Pending CN105658222A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN201910526464.9A Pending CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体

Country Status (13)

Country Link
US (1) US9630971B2 (enExample)
EP (2) EP3010509B1 (enExample)
JP (2) JP6865036B2 (enExample)
KR (2) KR20160040522A (enExample)
CN (3) CN112851683A (enExample)
AU (1) AU2014284224B2 (enExample)
BR (1) BR112015032132B1 (enExample)
CA (1) CA2916393C (enExample)
ES (1) ES2894770T3 (enExample)
IL (2) IL267331B2 (enExample)
MX (2) MX2015017972A (enExample)
RU (1) RU2675851C2 (enExample)
WO (1) WO2014205354A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
EP3010509B1 (en) 2013-06-21 2021-07-28 Intra-Cellular Therapies, Inc. Free base crystals
EP4413980A3 (en) 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
US12435093B2 (en) 2020-05-06 2025-10-07 Intra-Cellular Therapies, Inc. Free base crystals
JP2023535224A (ja) * 2020-07-26 2023-08-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP4395767A4 (en) * 2021-09-03 2025-07-23 Intra Cellular Therapies Inc CO-CRYSTALS
US20250144029A1 (en) * 2022-01-27 2025-05-08 Intra-Cellular Therapies, Inc. Novel compositions
WO2023233410A1 (en) * 2022-06-02 2023-12-07 Biosight Ltd. Crystalline form of aspacytarabine intermediate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970444A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
CN104602695A (zh) * 2012-06-21 2015-05-06 细胞内治疗公司 盐晶体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US5471001A (en) * 1994-12-15 1995-11-28 E. I. Du Pont De Nemours And Company Crystallization of adipic acid
GB9624615D0 (en) 1996-11-26 1997-01-15 Zeneca Ltd Chrystallisation process
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
WO2003066590A1 (en) 2002-02-08 2003-08-14 Ono Pharmaceutical Co., Ltd. Piperidine derivative compounds and drugs containing the compounds as the active ingredient
EP1613747A1 (en) * 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
AU2004268024B2 (en) 2003-09-02 2007-07-12 Merck Sharp & Dohme Llc Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
DK1794126T3 (da) * 2004-09-27 2013-06-24 Acadia Pharm Inc Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat
CN101248050B (zh) 2005-06-06 2013-07-17 武田药品工业株式会社 有机化合物
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
EP2367429B1 (en) 2008-12-06 2017-06-07 Intra-Cellular Therapies, Inc. Organic compounds
EP2358204B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
CN102232077A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE-1-HEMMER FOR EYE DRESSING
US9468637B2 (en) * 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP2013507360A (ja) 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
EP3010509B1 (en) 2013-06-21 2021-07-28 Intra-Cellular Therapies, Inc. Free base crystals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970444A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
CN104602695A (zh) * 2012-06-21 2015-05-06 细胞内治疗公司 盐晶体

Also Published As

Publication number Publication date
ES2894770T3 (es) 2022-02-15
EP3010509A4 (en) 2016-11-23
KR20210122890A (ko) 2021-10-12
AU2014284224B2 (en) 2019-08-01
MX2015017972A (es) 2016-10-28
AU2014284224A1 (en) 2016-02-11
BR112015032132B1 (pt) 2022-03-15
EP3702358A1 (en) 2020-09-02
IL243269B (en) 2019-06-30
WO2014205354A3 (en) 2015-05-28
RU2675851C2 (ru) 2018-12-25
MX2020001628A (es) 2020-07-13
IL267331A (en) 2019-08-29
KR20160040522A (ko) 2016-04-14
CA2916393C (en) 2022-03-22
EP3010509A2 (en) 2016-04-27
RU2016101630A3 (enExample) 2018-03-21
RU2016101630A (ru) 2017-07-26
JP2016523258A (ja) 2016-08-08
CN110498800A (zh) 2019-11-26
HK1223848A1 (zh) 2017-08-11
US9630971B2 (en) 2017-04-25
JP2019189618A (ja) 2019-10-31
KR102430126B1 (ko) 2022-08-05
BR112015032132A2 (pt) 2017-07-25
CA2916393A1 (en) 2014-12-24
IL243269A0 (en) 2016-02-29
IL267331B1 (en) 2024-08-01
WO2014205354A2 (en) 2014-12-24
US20160145261A1 (en) 2016-05-26
CN105658222A (zh) 2016-06-08
IL267331B2 (en) 2024-12-01
JP6865036B2 (ja) 2021-04-28
EP3010509B1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
CN112851683A (zh) 游离碱晶体
CN104602695B (zh) 盐晶体
CN108699063A (zh) 一种芦可替尼的合成工艺
US12435093B2 (en) Free base crystals
HK40036801A (en) Process for preparing salts of a known pde1 inhibitor
HK1223848B (en) Free base crystals
HK1247191A1 (en) Salt crystals
HK1210017B (en) Salt crystals of a pde1 inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination